Safety Profile Overview
JAK1/JAK2 inhibitor for rheumatoid arthritis and alopecia areata. Shares the JAK inhibitor class-wide boxed warnings for serious events.
Generic Name
baricitinib
Brand Names
Olumiant
Therapeutic Class
JAK Inhibitor
Manufacturer
Eli Lilly
What Pharma Signal Tracks for Olumiant
- Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Olumiant, including serious outcomes, hospitalizations, and deaths.
- FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Olumiant products.
- Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
- Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
- Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
- Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.
Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.
Get Olumiant Safety Data via API
One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Olumiant.
curl "https://api.pharma-signal.com/drug/safety/olumiant" \ -H "X-API-Key: your_key" # Returns risk score, adverse event counts, # serious/death rates, recalls, and signals
Related Safety Intelligence
Pharma Signal provides comparative analysis across therapeutic classes. Compare Olumiant against other JAK Inhibitor drugs, or explore the full manufacturer portfolio for Eli Lilly.
- Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
- Therapeutic class benchmarking — See how Olumiant ranks within JAK Inhibitor on serious event rates.
- Company portfolio risk — View all drugs from Eli Lilly with aggregate risk exposure.
- AI analyst briefs — Get a natural-language safety assessment combining all data sources.